AlanSubie4Life
Efficiency Obsessed Member
Perhaps we don't, but I would be shocked if it's more transmissible than B.1.1.7 based on the current state of affairs in Israel (and elsewhere). I don't think that is just due to founder effects!Do we really know that B.1.351 is less transmissible than B.1.1.7? I don’t recall seeing any high-quality evidence yet.
As for B.1.351 vs wildtype (original “Wuhan” variant) I think “351” near fully displaced the original variant in South Africa which tends to imply that it is more transmissible.
It does appear that they believe B.1.351 is more transmissible than wildtype. I guess that's not too difficult a bar to pass over though.
You can look through per country tracking here. It looks like B.1.351 is pretty transmissible, but it definitely looks like B.1.1.7 outcompetes it (you can see Turkey for example where B.1.1.7 is gaining in spite of a big head start by B.1.351). Obviously this data is subject to reporting biases, etc. There are some places where B.1.351 is getting a foothold (Romania, Singapore, for example - again, there may be biases at play here).
I just have a hard time, given how long it's been around, believing that it can outcompete B.1.1.7.
Also remember when looking at this data, one thing that helps B.1.351 is that it escapes natural immunity (while B.1.1.7 is not as likely to do so), and that's not going to hold to the same degree for the vaccines (look at the results of the Israel study above, 8x better at breaking through perhaps, but starting from a dramatically reduced level...). So just because B.1.351 is doing better in a particular location doesn't mean it is more transmissible - at this point. It just may have other advantages which lead to higher effective transmission rates.
Last edited: